Abstract: Trichosporon spp. are yeast-like microorganisms responsible for skin, urinary, pulmonary, or bloodstream infections. Due to intrinsic resistance to echinocandins, poor susceptibility to polyenes, and preferred occurrence in immunocompromised patients, such infections are often of poor prognosis. Yet no consensual therapeutic guidelines are presently available. Several clinical cases of Trichosporon infections have been successfully treated with azole therapy, including voriconazole which appeared frequently effective against Trichosporon both in vitro and in vivo. However, the low efficacy associated with some Trichosporon genotypes, complex pharmacokinetics, and the side effects of voriconazole represent limitations for its use and has prompted a search for other therapeutic options. Here, we report a case of T. asahii fungemia in a patient with B-cell acute lymphoblastic leukemia which was successfully treated with isavuconazole consecutive to stopping voriconazole therapy due to severe side effects. This observation suggests that isavuconazole with a similar spectrum to voriconazole, fewer pharmacology interactions, and side effects may be considered as a valuable therapeutic option against Trichosporon infections.
Case
Trichosporon species are a common cause of fungemia after Candida species in patients with hematologic malignancies. Among all species, Trichosporon asahii is the most frequently implicated. Several fatal cases of Trichosporon asahii infections have been reported, and early use of an appropriate antifungal appears essential for survival. While Trichosporon spp. exhibits intrinsic resistance to echinocandins and amphotericin B, azoles appear to be the most constantly effective agents, and voriconazole has been successfully used in clinical cases although no well-documented consensus guidelines are presently available. [1] [2] [3] Here, we report a case of a T.asahii infection which was successfully treated with isavuconazole in a patient suffering from hematologic malignancies.
A 
G/L and finally 10.3 G/L on July 18th, August 1st, August 3rd, August 7th to 16th and August 20th, respectively. Two days consecutively to voriconazole introduction, on July 20th, voriconazole plasma concentration was 4.9 µg/mL, increasing to 6.5 µg/mL on July 26th (N: 1-5µg/mL). Consecutively to this dosage and due to neurological adverse effects, voriconazole dose was decreased from 4 mg/kg to 2 mg/kg every 12 hrs. Four days later, on July 30th voriconazole plasma concentration was within the normal range at 1.1 µg/mL (N: 1-5 µg/ml). On August 1st, the patient had grade III neurological toxicity with persistent invalidating hallucinations and voriconazole therapy was discontinued. Within two days of liposomal amphotericin B monotherapy, erythematous skin lesions appeared on the patient's right thigh and disseminated in a few days (biopsy confirmed T. asahii infection) even with leucocyte concentrations ranging between 2.8 and 5 G/L. On August 13th, based on MIC results, isavuconazole (IV 200 mg twice a day) was added to liposomal amphotericin B therapy. Two days later, the infection declined with regression of skin lesions and culture-negative results. Isavuconazole (IV) was then used at 200 mg a day for 2 weeks and then, orally at the same dose for 3 months (Figure 1) . Finally, the fungemia was successfully treated with an isavuconazole-based therapy. Eleven months later (to date with the current report), the patient is still in complete remission from his underlying pathology.
In this reported case, we observed both the inefficacy of amphotericin B-based therapy and successful treatment with isavuconazole. Immune restoration probably potentiated the efficacy of isavuconazole. However, it is difficult to attribute recovery to immune restoration alone since the patient had leucocytes ranging from 4.5 to 5 G/L for 6 days before isavuconazole initiation and infection was out of control. In this patient, several previously identified conditions promoting Trichosporon infection were present. In the present case, immunodepression was associated with malignant hemopathies, and the additional role of anti-CD3 and anti-CD19 blinatumomab therapy for the treatment of acute lymphoid leukemia requires further investigation. Moreover, among a Isolate 1 was obtained from blood culture 7 days after initiation of empiric caspofungin treatment (one month before isavuconazole therapy). Isolate 2 was obtained from cutaneous biopsy the day voriconazole therapy was stopped (12 days before isavuconazole therapy). risk factors our patient presented hemochromatosis. Indeed, in 2010, Shih-Ta Shang et al described Trichosporon fungemia in an immunocompetent patient with hemochromatosis. 4 They hypothesized that iron overload decreased T-cell immunity, natural killer cell, and neutrophil activities and monocyte phagocytosis. Additionally, our patient had a vascular catheter that was removed after Trichosporon infection diagnosis and was suspected as the source of fungemia.
No consensus guidelines are currently available for the treatment of Trichosporon infections even if voriconazole is presented as a preferred therapy. Voriconazole, however, may interact with several other pharmaceutical agents. In additon, high intra-and interindividual pharmacokinetic variability is well established and can easily cause over-or underdosing. Consequently, many side effects of voriconazole therapy have been observed such as hallucinations which led to treatment discontinuation in our case. These side effects require a search for alternative therapeutic options. Isavuconazole has exhibited an excellent in vitro activity against Trichosporon. 5 In the present clinical case, voriconazole, used in first intention with amphotericin B, was discontinued due to side effects. Isavuconazole administration resulted in improved skin lesions and finally fungemia was controlled in absence of side effects. This observation suggests that isavuconazole with fewer side effects and similar efficiency against Trichosporon spp. compared with voriconazole should be considered as a valuable alternative to voriconazole in Trichosporon infections.
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